Are Celgene Corporation (CELG) Option Traders Changing Their Tune?

Celgene Corporation (CELG) is muscling higher, sparking a rare wave of call buying

Mar 16, 2015 at 10:52 AM
facebook twitter linkedin


Biotech stocks are mostly higher this morning, and Celgene Corporation (NASDAQ:CELG) is no exception. The stock -- which will join the S&P 500 Index (SPX) after the close on Friday -- is up 1.7% at $119.77, and option traders are gambling on even more short-term upside for the equity.

Intraday call volume is running at nearly twice the average clip, and has outpaced CELG put volume by a margin of roughly 5-to-1. Possible buy-to-open activity has been detected at the March 120 call, as speculators bet on CELG to muscle north of $120 through the end of the week, which represents the front-month contracts' life span. In light of CELG's ascent today, delta on the call has jumped to 0.47 from 0.33 at Friday's close, implying a near 1-in-2 shot of the option expiring in the money.

Today's appetite for CELG's short-term calls marks a change of pace for the equity. The stock's Schaeffer's put/call open interest ratio (SOIR) of 1.35 sits just 6 percentage points from an annual peak, suggesting near-term traders have rarely been more put-biased during the past year.

On the charts, Celgene Corporation (NASDAQ:CELG) is 6.8% higher year-to-date, and since touching a record high of $125.45 in late February, has pulled back to test the waters atop its 60-day moving average. This trendline has contained CELG's dips in 2015, and could continue to serve as support.

Bernie's Best Stock Bets for Summer 2021

1608308875

 




 
Special Offers from Schaeffer's Trading Partners